When the cyclin kinase 4/6 inhibitor abemaciclib was sequenced with PD-1 blockade in mostly immunologically “cold” murine models, enhanced immune-mediated antitumor effects—including increased lifespan, recruitment of CD8 cells to tumor, reduction of regulatory T-cell and immunosuppressive cytokines in tumor, increased tumor antigen presentation, and broadening of the T-cell receptor repertoire—were achieved in both cutaneous and brain metastases.

See related article by Nayyar et al., p. 420

You do not currently have access to this content.